[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI941133A0 - Koostumus ja menetelmä hepatiitti C:n hoitamiseksi - Google Patents

Koostumus ja menetelmä hepatiitti C:n hoitamiseksi

Info

Publication number
FI941133A0
FI941133A0 FI941133A FI941133A FI941133A0 FI 941133 A0 FI941133 A0 FI 941133A0 FI 941133 A FI941133 A FI 941133A FI 941133 A FI941133 A FI 941133A FI 941133 A0 FI941133 A0 FI 941133A0
Authority
FI
Finland
Prior art keywords
thymosin
composition
treating hepatitis
immune system
potentiating
Prior art date
Application number
FI941133A
Other languages
English (en)
Swedish (sv)
Other versions
FI941133A (fi
FI107879B (fi
Inventor
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc filed Critical Alpha 1 Biomedicals Inc
Publication of FI941133A0 publication Critical patent/FI941133A0/fi
Publication of FI941133A publication Critical patent/FI941133A/fi
Application granted granted Critical
Publication of FI107879B publication Critical patent/FI107879B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
FI941133A 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi FI107879B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13
US75954491 1991-09-13
US9207556 1992-09-08
PCT/US1992/007556 WO1993005806A1 (en) 1991-09-13 1992-09-08 Composition and method of treating hepatitis c

Publications (3)

Publication Number Publication Date
FI941133A0 true FI941133A0 (fi) 1994-03-10
FI941133A FI941133A (fi) 1994-03-10
FI107879B FI107879B (fi) 2001-10-31

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941133A FI107879B (fi) 1991-09-13 1994-03-10 Menetelmä hepatiitti C:n hoitamiseen tarkoitetun koostumuksen valmistamiseksi

Country Status (23)

Country Link
US (3) US6001799A (fi)
EP (1) EP0603305B1 (fi)
JP (1) JP3228512B2 (fi)
KR (1) KR100254082B1 (fi)
AT (1) ATE152914T1 (fi)
AU (1) AU667327B2 (fi)
CA (1) CA2119006C (fi)
CZ (1) CZ286827B6 (fi)
DE (1) DE69219782T2 (fi)
DK (1) DK0603305T3 (fi)
ES (1) ES2103966T3 (fi)
FI (1) FI107879B (fi)
GR (1) GR3024025T3 (fi)
HK (1) HK1021687A1 (fi)
HU (1) HU221006B1 (fi)
MX (1) MX9205240A (fi)
NO (1) NO941310L (fi)
RO (1) RO111991B1 (fi)
RU (1) RU2104010C1 (fi)
SG (1) SG64897A1 (fi)
TW (1) TW224053B (fi)
WO (1) WO1993005806A1 (fi)
ZA (1) ZA926964B (fi)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (fi) * 1991-09-13 1994-05-21 Paul B Chretien
WO1995011688A1 (en) * 1992-02-06 1995-05-04 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
WO1994001125A1 (en) * 1992-07-13 1994-01-20 Sherman Kenneth E Composition and method of treating hepatitis b
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (fi) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
EP0731710B1 (en) * 1993-11-05 2003-05-14 Alpha 1 Biomedicals, Inc. Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
KR100394382B1 (ko) * 1996-02-28 2004-02-05 유니하트 코포레이션 천연사람α-인터페론으로구성된약학조성물
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2001272923A1 (en) 2000-05-26 2001-12-11 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
CN1446096A (zh) * 2000-08-07 2003-10-01 希克龙制药公司 使用胸腺素、干扰素和利巴韦林治疗丙型肝炎
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
CA2460341A1 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
KR100902197B1 (ko) * 2001-10-26 2009-06-11 로드아일랜드하스피틀 티모신에 의한 유전적 면역화 증대
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
AU2003217402A1 (en) * 2002-02-14 2003-09-04 Pharmasset Inc Modified fluorinated nucleoside analogues
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
AP2005003212A0 (en) 2002-06-28 2005-03-31 Centre Nat Rech Scient Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections.
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
KR20050109918A (ko) 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드의 제조 방법
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
MXPA05010391A (es) * 2003-03-28 2005-11-04 Sciclone Pharmaceuticals Inc Composicion para el tratamiento de infecciones por aspergillus con timosina alfa 1.
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CN1852915A (zh) 2003-07-25 2006-10-25 艾登尼科斯（开曼）有限公司 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
WO2006031725A2 (en) 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US7781576B2 (en) 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8337828B2 (en) * 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Sciences, Inc. Nucleoside phosphoramidates
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
EP2427213B1 (en) 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
HUE034239T2 (en) 2010-03-31 2018-02-28 Gilead Pharmasset Llc Method for Crystallization of (S) -isopropyl 2 - (((S) (perfluorophenoxy) (phenoxy) phosphoryl) amino) propanoate \ t
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (fi) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
CZ286827B6 (cs) 2000-07-12
US5849696A (en) 1998-12-15
HU9400758D0 (en) 1994-06-28
HUT75166A (en) 1997-04-28
JPH06510998A (ja) 1994-12-08
CZ55194A3 (en) 1994-10-19
US6001799A (en) 1999-12-14
NO941310D0 (no) 1994-04-12
MX9205240A (es) 1993-07-01
AU2644792A (en) 1993-04-27
SG64897A1 (en) 1999-05-25
KR100254082B1 (ko) 2000-09-01
WO1993005806A1 (en) 1993-04-01
JP3228512B2 (ja) 2001-11-12
RO111991B1 (ro) 1997-04-30
EP0603305A1 (en) 1994-06-29
ES2103966T3 (es) 1997-10-01
FI941133A (fi) 1994-03-10
RU94022480A (ru) 1996-07-20
NO941310L (no) 1994-04-12
HK1021687A1 (en) 2000-06-23
ZA926964B (en) 1993-04-26
ATE152914T1 (de) 1997-05-15
DK0603305T3 (da) 1997-09-01
AU667327B2 (en) 1996-03-21
DE69219782D1 (de) 1997-06-19
TW224053B (fi) 1994-05-21
FI107879B (fi) 2001-10-31
US20070218033A1 (en) 2007-09-20
RU2104010C1 (ru) 1998-02-10
HU221006B1 (hu) 2002-07-29
EP0603305B1 (en) 1997-05-14
GR3024025T3 (en) 1997-10-31
DE69219782T2 (de) 1997-10-09
CA2119006C (en) 2005-08-23
CA2119006A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
FI941133A0 (fi) Koostumus ja menetelmä hepatiitti C:n hoitamiseksi
EP0219524A1 (en) TREATMENT OF THE RESPIRATORY SYNDROME IN ADULTS.
GR3022969T3 (en) Products for the treatment of endotoxic shock in a mammal
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
ES2149776T3 (es) Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
FI943028A (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
ATE76579T1 (de) Interferon-zusammensetzungen.
DK0396903T3 (da) Anvendelse af IFN-gamma til fremstilling af et farmaceutisk præparat til behandling af ATL
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
DE3750886D1 (de) Verwendung eines immunglobulinhaltigen Präparates zur Prophylaxe und Therapie von AIDS beim Menschen.
GR3024907T3 (en) Antivenom immunesera
NO953473L (no) Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling
EP0452360A4 (en) Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections
DE69030181D1 (de) Verwendung von cromakalim/brl 38227 zur behandlung der überreaktivität der luftwege
NO933628D0 (no) Fremgangsmaate og blanding for behandling av herpes-infeksjoner
MY110041A (en) Composition and method of treating hepatitis c
MY109685A (en) Method for treating hepatitis b carriers with minimal disease

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

GB Transfer or assigment of application

Owner name: ALPHA 1 BIOMEDICALS, INC.

MM Patent lapsed